29.02 USD
▲-0.42+1.19%
2026-08-03
市值
$17.76B
市盈率
21.64
EPS
1.31
股息率
—
52 周区间
21.00 – 35.43
成交量
1.32M
Beta
0.69
目标价
37.96
52W 低 21.0052W 高 35.43
价格走势
公司简介
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n...